Form 4: ALX Oncology Director Granted Stock Options

ALX Oncology Holdings Inc. Director Chris H. Takimoto was granted 40,400 stock options with an exercise price of $1.32, vesting over 12 months.

Summary

• Chris H. Takimoto, a Director of ALX Oncology Holdings Inc. (ALXO), acquired 40,400 stock options.
• The stock options have an exercise price of $1.32 per share.
• The options were granted on January 20, 2026, and will expire on January 19, 2036.
• The shares subject to the option will vest in 12 equal monthly installments, commencing on February 20, 2026.
• Following this transaction, Chris H. Takimoto directly beneficially owns 40,400 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as an equity grant to a director generally aligns interests with shareholders, but it is a routine disclosure and not indicative of significant operational or financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.

Future Outlook

NA

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, aiming to attract and retain talent while aligning their financial incentives with the company's long-term success and shareholder value creation. This is a routine equity compensation event.

Related Party Transactions

• The grant of 40,400 stock options to Chris H. Takimoto, a Director of ALX Oncology Holdings Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially fostering long-term growth.
• Employees: While this specific grant is to a director, it is part of a broader compensation strategy that can impact employee morale and retention if similar equity incentives are offered across the organization.

Next Steps

• The stock options will vest in 12 equal monthly installments beginning on February 20, 2026.

Key Dates

Keywords

ALX Oncology, ALXO, stock option, insider transaction, Form 4, director, equity grant, beneficial ownership